Digital Health, Artificial Intelligence & Internet of Everything
We empower clients to capitalize on Digital Health, AI, and IoE - accelerating success in these emerging fields. Leveraging robust research capabilities, we deliver strategic insights enabling partners to build winning solutions and gain a competitive edge.
We empower Pharma, Biotech, Healthcare and HealthTech/MedTech companies to capitalize on Digital Health, AI and IoE, accelerating their competitive advantage.
As trusted partners, we provide strategic support spanning areas such as:
- Collaborative projects with BioPharma innovation units and patient solution teams
- Intensive patient-centricity research, placing the end-user at the heart of every solution
- Trend analysis in AI, wearable tech, digital therapeutics, and comprehensive digital health solutions
- Creation and support in AI-powered tool development for enhanced data intelligence
- Joint strategy formulation for competitive digital health and AI initiatives
- Pioneering research on the transformative impact of AI/IoE on healthcare, from “smart” homes to “smart” appliances
With robust research and consulting, we deliver evidence-based solutions, enabling clients to implement winning digital strategies.
Ready to accelerate innovation?
Let’s build winning tech strategies together. Contact us at info@lqventures.com.
April 30, 2026
Respiratory Today—April 30, 2026
April 30, 2026
Cell and Gene Therapy Today—April 30, 2026
April 30, 2026
Lucid Diligence Brief: Chiesi to acquire KalVista Pharmaceuticals
April 30, 2026
Rare Diseases Today—April 30, 2026
April 30, 2026
Cardiovascular Today—April 30, 2026
April 30, 2026
Lucid Diligence Brief: Teva to acquire Emalex Biosciences
April 29, 2026
Lucid Diligence Brief: Coultreon Biopharma Raises $125M for SIK3 Inhibitor
April 29, 2026
Women’s Health Today—April 29, 2026
April 29, 2026
Immunology Today—April 29, 2026
April 29, 2026
Neuroscience Today—April 29, 2026
April 29, 2026
Lucid Diligence Brief: Profluent-Lilly AI-Designed Recombinase Partnership
April 28, 2026